Don’t Jump to Trelegy for Asthma

November 2020

The “three-in-one” Trelegy Ellipta inhaler is now approved for ASTHMA...not just for COPD.

Trelegy contains the inhaled corticosteroid (ICS) fluticasone furoate...the long-acting beta-agonist (LABA) vilanterol...and the long-acting muscarinic antagonist (LAMA) umeclidinium.

Trelegy seems to improve lung function in asthma patients not controlled on a medium- or high-dose ICS/LABA...but isn’t yet shown to reduce exacerbations.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Practice Point Out Limitations of COVID-19 Antibody Testing
Substance Use Disorder Stay Alert for Unexpected Rx and OTC Med Misuse
Asthma Don’t Jump to Trelegy for Asthma
Fever Improve Accuracy of Noncontact Infrared Thermometers
Practice Evaluate if Guidelines “Fit” Your Patients
Supplements Clear Up Confusion About “Memory Supplements”
Med Administration Know When to Give Patients a “Green Light” to Cut or Crush Meds
Multiple Sclerosis Be Familiar With the Latest Oral Multiple Sclerosis Meds
Depression Offer Resources for Perinatal Depression
Medicare Expect Changes for Medicare Part D in 2021
Infectious Diseases Answer Questions About Using Steroids for COVID-19
Hemorrhage Optimize Safe Use of IV Tranexamic Acid
Infectious Diseases Sort Through Options for ESBL, CRE, and Resistant Pseudomonas
Nausea & Vomiting Combine Antiemetics and Peri-Op Strategies for PONV Prophylaxis

Don’t Jump to Trelegy for Asthma

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Table of Contents